Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

October 01, 1996; Volume 50,Issue 4
  • You have access
    Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit.
    K Williams, J Chao, K Kashiwagi, T Masuko and K Igarashi
    Molecular Pharmacology October 1996, 50 (4) 701-708;
  • You have access
    Identification and characterization of novel somatostatin antagonists.
    R T Bass, B L Buckwalter, B P Patel, M H Pausch, L A Price, J Strnad and J R Hadcock
    Molecular Pharmacology October 1996, 50 (4) 709-715;
  • You have access
    Agonist binding and protein kinase C activation stimulate phosphorylation of the gastrin-releasing peptide receptor at distinct sites.
    B Y Williams, Y Wang and A Schonbrunn
    Molecular Pharmacology October 1996, 50 (4) 716-727;
  • You have access
    Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
    D L Gustafson, H D Beall, E M Bolton, D Ross and C A Waldren
    Molecular Pharmacology October 1996, 50 (4) 728-735;
  • You have access
    Structural determinants of substrates for the prostaglandin transporter PGT.
    S Itoh, R Lu, Y Bao, J D Morrow, L J Roberts and V L Schuster
    Molecular Pharmacology October 1996, 50 (4) 736-742; DOI: https://doi.org/10.1124/mol.50.4.736
  • You have access
    Enhanced angiotensin receptor type 1 mRNA degradation and induction of polyribosomal mRNA binding proteins by angiotensin II in vascular smooth muscle cells.
    G Nickenig and T J Murphy
    Molecular Pharmacology October 1996, 50 (4) 743-751;
  • You have access
    5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
    O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion
    Molecular Pharmacology October 1996, 50 (4) 752-762;
  • You have access
    Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells.
    L Nie, H Mogami, M Kanzaki, H Shibata and I Kojima
    Molecular Pharmacology October 1996, 50 (4) 763-769;
  • You have access
    Ligand-binding characteristics and related structural features of the expressed goldfish kainate receptors: identification of a conserved disulfide bond and three residues important for ligand binding.
    Z G Wo and R E Oswald
    Molecular Pharmacology October 1996, 50 (4) 770-780;
  • You have access
    Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2a6: role in metabolic activation of nasal toxicants.
    C Liu, X Zhuo, F J Gonzalez and X Ding
    Molecular Pharmacology October 1996, 50 (4) 781-788;
  • You have access
    Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe.
    A P Kennedy, K C Mangum, J Linden and J N Wells
    Molecular Pharmacology October 1996, 50 (4) 789-798;
  • You have access
    Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.
    H Canton, R B Emeson, E L Barker, J R Backstrom, J T Lu, M S Chang and E Sanders-Bush
    Molecular Pharmacology October 1996, 50 (4) 799-807;
  • You have access
    Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
    S K Alahari, N M Dean, M H Fisher, R Delong, M Manoharan, K L Tivel and R L Juliano
    Molecular Pharmacology October 1996, 50 (4) 808-819;
  • You have access
    Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
    A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal
    Molecular Pharmacology October 1996, 50 (4) 820-828;
  • You have access
    Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathway.
    L A Price, J Strnad, M H Pausch and J R Hadcock
    Molecular Pharmacology October 1996, 50 (4) 829-837;
  • You have access
    Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
    C Sissi, G Capranico, E Menta and M Palumbo
    Molecular Pharmacology October 1996, 50 (4) 838-845;
  • You have access
    Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
    W E Robinson, M Cordeiro, S Abdel-Malek, Q Jia, S A Chow, M G Reinecke and W M Mitchell
    Molecular Pharmacology October 1996, 50 (4) 846-855;
  • You have access
    Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid.
    M C Wright, X J Wang, M Pimenta, V Ribeiro, A J Paine and M C Lechner
    Molecular Pharmacology October 1996, 50 (4) 856-863;
  • You have access
    Inhibition by toxin B of inositol phosphate formation induced by G protein-coupled and tyrosine kinase receptors in N1E-115 neuroblastoma cells: involvement of Rho proteins.
    C Zhang, M Schmidt, C von Eichei-Streiber and K H Jakobs
    Molecular Pharmacology October 1996, 50 (4) 864-869;
  • You have access
    Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle.
    K S Murthy and G M Makhlouf
    Molecular Pharmacology October 1996, 50 (4) 870-877;
  • You have access
    Acemannan, a beta-(1,4)-acetylated mannan, induces nitric oxide production in macrophage cell line RAW 264.7.
    L Ramamoorthy, M C Kemp and I R Tizard
    Molecular Pharmacology October 1996, 50 (4) 878-884;
  • You have access
    Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation.
    B R Conklin, P Herzmark, S Ishida, T A Voyno-Yasenetskaya, Y Sun, Z Farfel and H R Bourne
    Molecular Pharmacology October 1996, 50 (4) 885-890;
  • You have access
    Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
    S Jacobitz, M M McLaughlin, G P Livi, M Burman and T J Torphy
    Molecular Pharmacology October 1996, 50 (4) 891-899;
  • You have access
    DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes.
    M MacFarlane, N A Jones, C Dive and G M Cohen
    Molecular Pharmacology October 1996, 50 (4) 900-911;
  • You have access
    Functional coupling of rat group II metabotropic glutamate receptors to an omega-conotoxin GVIA-sensitive calcium channel in human embryonic kidney 293 cells.
    B A McCool, J P Pin, P F Brust, M M Harpold and D M Lovinger
    Molecular Pharmacology October 1996, 50 (4) 912-922;
  • You have access
    Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists.
    J Gomeza, S Mary, I Brabet, M L Parmentier, S Restituito, J Bockaert and J P Pin
    Molecular Pharmacology October 1996, 50 (4) 923-930;
  • You have access
    Endogenous subunits can cause ambiguities in the pharmacology of exogenous gamma-aminobutyric acidA receptors expressed in human embryonic kidney 293 cells.
    S Ueno, C Zorumski, J Bracamontes and J H Steinbach
    Molecular Pharmacology October 1996, 50 (4) 931-938;
  • You have access
    Block of high-threshold calcium channels by the synthetic polyamines sFTX-3.3 and FTX-3.3.
    T M Norris, E Moya, I S Blagbrough and M E Adams
    Molecular Pharmacology October 1996, 50 (4) 939-946;
  • You have access
    Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors.
    E T Piros, P L Prather, P Y Law, C J Evans and T G Hales
    Molecular Pharmacology October 1996, 50 (4) 947-956;
  • You have access
    Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter.
    E L Barker and R D Blakely
    Molecular Pharmacology October 1996, 50 (4) 957-965;
  • You have access
    Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors.
    V J Watts and K A Neve
    Molecular Pharmacology October 1996, 50 (4) 966-976;
  • You have access
    Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
    S A Hjorth, K Thirstrup and T W Schwartz
    Molecular Pharmacology October 1996, 50 (4) 977-984;
  • You have access
    Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
    M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi
    Molecular Pharmacology October 1996, 50 (4) 985-993;
  • You have access
    The antioxidant function of the physiological content of vitamin C.
    P A Glascott, M Tsyganskaya, E Gilfor, M A Zern and J L Farber
    Molecular Pharmacology October 1996, 50 (4) 994-999;
  • You have access
    Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.
    S M Yu, S F Chen, Y T Lau, C M Yang and J C Chen
    Molecular Pharmacology October 1996, 50 (4) 1000-1009;
  • You have access
    Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino-terminal domain of the receptor.
    D Yu, L Zhang, J L Eiselé, D Bertrand, J P Changeux and F F Weight
    Molecular Pharmacology October 1996, 50 (4) 1010-1016;
  • You have access
    5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism.
    K A Berg, S Maayani and W P Clarke
    Molecular Pharmacology October 1996, 50 (4) 1017-1023;
  • You have access
    Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist.
    D Ragozzino, R M Woodward, Y Murata, F Eusebi, L E Overman and R Miledi
    Molecular Pharmacology October 1996, 50 (4) 1024-1030;
  • You have access
    Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist.
    N Nishigaki, M Negishi and A Ichikawa
    Molecular Pharmacology October 1996, 50 (4) 1031-1037;
  • You have access
    m3 Muscarinic receptor-induced and Gi-mediated heterologous potentiation of phospholipase C stimulation: role of phosphoinositide synthesis.
    M Schmidt, C Nehls, U Rümenapp and K H Jakobs
    Molecular Pharmacology October 1996, 50 (4) 1038-1046;
  • You have access
    Pituitary adenylate cyclase-activating peptide, carbachol, and glucose stimulate insulin release in the absence of an increase in intracellular Ca2+.
    M Komatsu, T Schermerhorn, S G Straub and G W Sharp
    Molecular Pharmacology October 1996, 50 (4) 1047-1054;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 50, Issue 4
1 Oct 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics